X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4123) 4123
female (2554) 2554
male (2357) 2357
quinazolines - adverse effects (2328) 2328
middle aged (2165) 2165
quinazolines - therapeutic use (2137) 2137
aged (1961) 1961
oncology (1956) 1956
quinazolines - administration & dosage (1569) 1569
adult (1566) 1566
lung neoplasms - drug therapy (1308) 1308
carcinoma, non-small-cell lung - drug therapy (1107) 1107
treatment outcome (1011) 1011
erlotinib hydrochloride (1006) 1006
gefitinib (1003) 1003
antineoplastic agents - therapeutic use (997) 997
antineoplastic agents - adverse effects (942) 942
chemotherapy (895) 895
cancer (822) 822
antineoplastic combined chemotherapy protocols - therapeutic use (809) 809
erlotinib (803) 803
receptor, epidermal growth factor - antagonists & inhibitors (767) 767
aged, 80 and over (735) 735
quinazolines - pharmacology (678) 678
protein kinase inhibitors - therapeutic use (645) 645
pharmacology & pharmacy (632) 632
protein kinase inhibitors - adverse effects (593) 593
care and treatment (578) 578
antineoplastic combined chemotherapy protocols - adverse effects (553) 553
lung neoplasms - pathology (542) 542
animals (535) 535
disease-free survival (526) 526
growth-factor receptor (479) 479
tyrosine kinase inhibitor (458) 458
epidermal growth factor (452) 452
mutation (443) 443
lung cancer, non-small cell (439) 439
quinazolines - pharmacokinetics (429) 429
therapy (426) 426
medicine & public health (425) 425
research (420) 420
carcinoma, non-small-cell lung - pathology (414) 414
dose-response relationship, drug (413) 413
receptor, epidermal growth factor - genetics (412) 412
hematology, oncology and palliative medicine (407) 407
breast neoplasms - drug therapy (384) 384
adenocarcinoma - drug therapy (382) 382
egfr (378) 378
neoplasm staging (378) 378
trial (377) 377
lung neoplasms - genetics (359) 359
cell lung-cancer (358) 358
drug therapy (358) 358
lung cancer (344) 344
antineoplastic agents - administration & dosage (340) 340
clinical trials (338) 338
drug administration schedule (327) 327
analysis (312) 312
survival (309) 309
clinical trials as topic (297) 297
carcinoma, non-small-cell lung - genetics (296) 296
lung neoplasms - mortality (294) 294
protein kinase inhibitors - administration & dosage (292) 292
open-label (284) 284
neoplasms - drug therapy (282) 282
expression (281) 281
survival analysis (278) 278
respiratory system (275) 275
carcinoma, non-small-cell lung - mortality (271) 271
lapatinib (269) 269
metastasis (269) 269
breast cancer (266) 266
trastuzumab (266) 266
non-small cell lung cancer (264) 264
antineoplastic agents (260) 260
combination (258) 258
deoxycytidine - analogs & derivatives (251) 251
pharmacokinetics (251) 251
disease progression (250) 250
tyrosine (249) 249
antibodies, monoclonal, humanized (247) 247
mice (246) 246
retrospective studies (244) 244
prognosis (239) 239
efficacy (238) 238
pharmacology/toxicology (236) 236
time factors (235) 235
epidermal growth factor receptor (234) 234
antimitotic agents (232) 232
antineoplastic agents - pharmacology (231) 231
receptor, epidermal growth factor - metabolism (231) 231
bevacizumab (230) 230
administration, oral (220) 220
1st-line treatment (219) 219
tumors (219) 219
inhibitor (217) 217
neoplasm metastasis (216) 216
risk factors (216) 216
double-blind method (213) 213
mutations (213) 213
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4147) 4147
Japanese (74) 74
Chinese (53) 53
French (48) 48
German (43) 43
Spanish (28) 28
Russian (10) 10
Italian (7) 7
Portuguese (7) 7
Czech (6) 6
Danish (6) 6
Polish (6) 6
Dutch (5) 5
Hungarian (4) 4
Norwegian (3) 3
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2008, Volume 58, Issue 4, pp. 545 - 570
Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails... 
Dermatology | CELL LUNG-CANCER | CHRONIC MYELOGENOUS LEUKEMIA | GROWTH-FACTOR RECEPTOR | PEGYLATED LIPOSOMAL DOXORUBICIN | PHASE-II TRIAL | RADIATION-RECALL DERMATITIS | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE-KINASE INHIBITOR | CHRONIC MYELOID-LEUKEMIA | HAND-FOOT SYNDROME | DERMATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Drug Eruptions - pathology | Humans | Antibodies, Monoclonal - adverse effects | Phenylurea Compounds | Protein Kinase Inhibitors - adverse effects | Benzenesulfonates - adverse effects | Antibodies, Monoclonal, Humanized | Pyridines - adverse effects | Fusion Proteins, bcr-abl | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug-Related Side Effects and Adverse Reactions | Hair Diseases - chemically induced | Pyrroles - adverse effects | Mucous Membrane - drug effects | Cetuximab | Taxoids - adverse effects | Platinum Compounds - adverse effects | Drug Eruptions - etiology | Skin Diseases - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Antimetabolites - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Pyrimidines - adverse effects | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Benzamides | Proteasome Inhibitors | Skin - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Chemotherapy | Platelet-derived growth factor | Formulae, receipts, prescriptions | Dermatologic agents | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2018, Volume 2018, Issue 4, pp. CD011746 - CD011746
Background Biliary tract cancers are a group of rare heterogeneous malignant tumours. They include intrahepatic and extrahepatic cholangiocarcinomas,... 
Medical interventions | MALIGNANT CHOLANGIOCARCINOMA INCLUDING PERIAMPULLAR CANCER (C24.1) (M8160/3) | Capecitabine | Organoplatinum Compounds | Tegafur | Gemcitabine‐based therapy | Biliary Tract Neoplasms | Gallbladder & bile duct disease | Quinazolines | Ampulla of Vater | MALIGNANT COMBINED HEPATO‐CELLULAR CHOLANGIOCARCINOMA (C22.0) (M8180/3) | Oxaliplatin | Oxonic Acid | Piperidines | Cholangiocarcinoma | Medical intervention | Chemotherapeutic agents | Mitomycin | Gastroenterology & hepatology | Antineoplastic Combined Chemotherapy Protocols | Cisplatin | Gallbladder cancer | Randomized Controlled Trials as Topic | Treatment | Deoxycytidine | Gallbladder Neoplasms | Antimetabolites, Antineoplastic | Other types of cancer | Medicine General & Introductory Medical Sciences | Drug Combinations | Cancer | MEDICINE, GENERAL & INTERNAL | INTRAHEPATIC CHOLANGIOCARCINOMA | RISK-FACTORS | RANDOMIZED PHASE-II | DESIGN CHARACTERISTICS | FINDINGS TABLES | EMPIRICAL-EVIDENCE | GALLBLADDER CANCER | POOLED ANALYSIS | SINGLE-AGENT GEMCITABINE | TRIAL SEQUENTIAL-ANALYSIS | Capecitabine - administration & dosage | Gallbladder Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biliary Tract Neoplasms - mortality | Cisplatin - administration & dosage | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Deoxycytidine - adverse effects | Female | Quinazolines - administration & dosage | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - pathology | Mitomycin - adverse effects | Piperidines - administration & dosage | Tegafur - adverse effects | Cholangiocarcinoma - mortality | Oxonic Acid - administration & dosage | Oxonic Acid - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - pathology | Gallbladder Neoplasms - drug therapy | Capecitabine - adverse effects | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Antimetabolites, Antineoplastic - adverse effects | Quinazolines - adverse effects | Cisplatin - adverse effects | Tegafur - administration & dosage | Gallbladder Neoplasms - pathology | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Journal Article
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2014, Volume 92, Issue 3, pp. 194 - 207
... (95% CI 0.60–1.19; p = 0.50), 2.36 (95% CI 0.95–5.87; p = 0.06), respectively. Exploratory subgroup analysis showed no effect of the agent used (sunitinib... 
Hematology, Oncology and Palliative Medicine | Hypertension | Left ventricular dysfunction | Sunitinib | Cardiovascular toxicities | Meta-analysis | 1ST-LINE TREATMENT | ADVANCED BREAST-CANCER | RENAL-CELL CARCINOMA | METASTATIC COLORECTAL-CANCER | LUNG-CANCER | HEPATOCELLULAR-CARCINOMA | INTERFERON-ALPHA | ONCOLOGY | RANDOMIZED PHASE-III | DOUBLE-BLIND | HEMATOLOGY | GASTROINTESTINAL STROMAL TUMORS | Humans | Risk | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Incidence | Neoplasms - complications | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Angiogenesis Inhibitors - therapeutic use | Cardiovascular Diseases - epidemiology | Pyrroles - adverse effects | Imidazoles - therapeutic use | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Cardiovascular Diseases - diagnosis | Pyridines - therapeutic use | Cardiovascular Diseases - etiology | Imidazoles - adverse effects | Phenylurea Compounds - therapeutic use | Neoplasms - drug therapy | Indoles - adverse effects | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Indoles - therapeutic use | Indazoles - adverse effects | Indazoles - therapeutic use | Antimitotic agents | Care and treatment | Cardiac patients | Comparative analysis | Antineoplastic agents | Risk factors | Tumors
Journal Article
The oncologist (Dayton, Ohio), ISSN 1549-490X, 2011, Volume 16, Issue 5, pp. 566 - 578
Src is believed to play an important role in cancer, and several agents targeting Src are in clinical development. Design. We reviewed Src structure and... 
Dasatinib | Solid tumor | Biologic | Bosutinib | Src inhibitors | Saracatinib | SARACATINIB AZD0530 | ACTIVATION | PROTEIN-TYROSINE KINASES | PHASE-II | CELL-CYCLE ARREST | DASATINIB BMS-354825 | GROWTH-FACTOR RECEPTOR | COLON-CANCER CELLS | ONCOLOGY | PROSTATE-CANCER | C-SRC | Humans | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Pyrimidines - chemistry | Thiazoles - adverse effects | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Benzodioxoles - adverse effects | Benzodioxoles - chemistry | Benzodioxoles - therapeutic use | Quinazolines - chemistry | Quinolines - chemistry | src-Family Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols | Clinical Trials as Topic | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Nitriles - chemistry | Pyrimidines - adverse effects | Quinazolines - adverse effects | Thiazoles - chemistry | Quinolines - therapeutic use | Aniline Compounds - chemistry | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Nitriles - adverse effects | src-Family Kinases - chemistry | src-Family Kinases - genetics | Quinolines - adverse effects | Nitriles - therapeutic use | Cancer Biology
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 5, pp. 876 - 884
...). Dose escalation was based on 3+3 design and used the Common Terminology Criteria for Adverse Events Version 4.0... 
Hematology, Oncology and Palliative Medicine | p70 S6 kinase inhibitor | LY2584702 tosylate | Erlotinib | Everolimus | CELL LUNG-CANCER | RAPAMYCIN | PHARMACOKINETICS | ONCOLOGY | PHOSPHORYLATION | GROWTH | TRANSLATION INITIATION | ACTIVE METABOLITE OSI-420 | Erlotinib Hydrochloride | Neoplasms - metabolism | Area Under Curve | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Metabolic Clearance Rate | Fatigue - chemically induced | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Time Factors | Adult | Female | Quinazolines - administration & dosage | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacokinetics | Sirolimus - adverse effects | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Sirolimus - analogs & derivatives | Drug Administration Schedule | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Pyrimidines - administration & dosage | Ribosomal Protein S6 Kinases, 70-kDa - antagonists & inhibitors | Treatment Outcome | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Sirolimus - administration & dosage | Vomiting - chemically induced | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Quinazolines - adverse effects | Pyrimidines - pharmacokinetics | Anorexia - chemically induced | Aged | Adaptor Proteins, Signal Transducing - metabolism | Neoplasms - pathology | Clinical trials | Care and treatment | Product development | Tumors | Life Sciences | Cancer
Journal Article
Journal of human genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
Rare but severe adverse drug reactions (ADRs) are an important issue in drug development and in the proper usage of drugs during the post-approval phase... 
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | HLA CLASS-I | TOXIC EPIDERMAL NECROLYSIS | CLASS-II GENOTYPE | GENETIC SUSCEPTIBILITY | RISK-FACTOR | GENETICS & HEREDITY | GENOME-WIDE | HLA-B-ASTERISK-1502 ALLELE | JAPANESE PATIENTS | STEVENS-JOHNSON-SYNDROME | ABACAVIR HYPERSENSITIVITY | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Flucloxacillin | Risk groups | DQA1 protein | Allopurinol | Hypersensitivity | Liver | Drug development | Carbamazepine | Genetic screening | Ticlopidine | Quality of life | Side effects | Genetic markers | Abacavir | Histocompatibility antigen HLA | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 1, pp. 64 - 71
Journal Article